Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Phase 4 Unknown 304 enrolled Tao OUYANG

RandomizedParallel-groupOpen-labelTreatment

This is a phase IV, single-center, prospective, open-label, randomized,controlled study

Evaluation	Drug	Modality	Dose	Route
Subject	Vinorelbine	Small molecule	25 mg/m2	—